

**Country: Ireland**

**Organisation: Health Research Board**

This document contains **information on specific requirements** for researchers applying for funding by the funding organisation indicated above. To make sure that your application is fully in line with the specific requirements and to receive latest information, please contact the respective **national contact person**. Not fulfilling the requirements may lead to ineligibility of the application.

### Contact

<b>National contact person</b>	Dr Caitriona Creely, ccreely@hrb.ie
--------------------------------	-------------------------------------

### Eligibility

<b>Eligible Institutions</b>	Please see <a href="http://www.hrb.ie/research-strategy-funding/policies-guidelines-and-grant-conditions/policies-and-position-statements/approval-of-host-institutions/">http://www.hrb.ie/research-strategy-funding/policies-guidelines-and-grant-conditions/policies-and-position-statements/approval-of-host-institutions/</a> for list of eligible institutions
<b>Additional requirements</b>	Proposals from Irish institutions that include human Embryonic Stem Cell Research will be deemed <b>ineligible</b>

### Budget

<b>Total earmarked national budget</b>	€370,000
<b>Anticipated no. of funded groups</b>	Anticipated number of funded research groups: 1-2, includes overhead and pension contribution
<b>Budget restrictions</b>	N/A, see eligible costs and eligible Host Institution policy
<b>Eligible costs</b>	<p>Funding available is inclusive of overheads and pension contributions</p> <ul style="list-style-type: none"> <li>• Salary related costs</li> <li>• small equipment costs</li> <li>• travel</li> <li>• direct running costs</li> <li>• dissemination and knowledge exchange costs</li> <li>• overheads</li> </ul> <p>(in accordance with the HRB Policy on Overhead Usage, the HRB will contribute to the indirect costs of the research through an overhead payment of 30% of Total Direct Modified Costs (TDMC excludes student fees, equipment and capital building costs) for <b>laboratory or clinically-based research</b> and 25% of Total Direct Modified Costs if <b>desk-based research</b>.)</p>